Milestone Pharmaceuticals MIST 深 沪
等待开盘 12-20 09:30:00 美东时间
2.115
+0.035
+1.68%
华盛通- 最 高2.1989
- 今 开2.08
- 成交量 441.40万股
- 最 低 2.08
- 昨 收 2.08
- 总市值 1.80亿
- 52周最高 3.06
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 0.6254
- 委 比 49.87%
- 总股本 8499.43万
- 历史最高 27.95
- 量 比 0.21
- 振 幅 5.72%
- 历史最低 0.6254
- 每 手 1
- 风险率 0.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股机会日报 | AI“循环交易”再现？OpenAI寻求亚马逊100亿美元投资；美股年内最大IPO今夜挂牌上市
AI“循环交易”再现？OpenAI寻求亚马逊100亿美元投资；美股今年最大IPO诞生，Medline今夜挂牌上市；Robotaxi利好引爆，特斯拉股价重回巅峰>>
12-17 21:09
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
12-17 10:46
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
12-16 09:36
TD Cowen Upgrades Milestone Pharmaceuticals to Buy, Announces $8 Price Target
TD Cowen analyst Ritu Baral upgrades Milestone Pharmaceuticals (NASDAQ:MIST) from Hold to Buy and announces $8 price target.
12-16 00:34
Market-Moving News for December 15th
RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Phase 2b Imaging Trial Of RAD 101 In Brain Metastases Showed That 92% Of The Patients Achieved Concordance With
12-15 20:26
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
Milestone Pharmaceuticals announced the FDA approval of CARDAMYST™, the first nasal spray treatment for PSVT in 30+ years, offering rapid self-administration outside emergency settings. The spray is a novel calcium channel blocker designed to quickly convert episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults, addressing a long-standing unmet need for over 2 million Americans. With robust clinical data supporting its eff...
12-13 01:00
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals Inc. granted 30,000 stock options to two new employees under its 2021 Inducement Plan, with a grant date of December 1, 2025, and an exercise price of $2.69 per share. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly. The awards are contingent on continued employment through each vesting date and comply with Nasdaq Listing Rule 5635(c)(4). Milestone is a biopharmaceutica...
12-02 22:21
Milestone Pharmaceuticals Prepares for CARDAMYST Launch Amid Financial Growth
Milestone Pharmaceuticals ( ($MIST) ) just unveiled an update. Milestone Pharma...
11-13 03:02
Milestone Pharmaceuticals Q3 EPS $(0.12) Beats $(0.16) Estimate
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 26.83 percent. This is a 14.29 percent increase over losses of $(0.14) per
11-12 20:03
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Milestone Pharmaceuticals reported a cash balance of $82.6 million as of September 30, 2025, and completed an equity offering raising approximately $48.7 million, enhancing its readiness for the potential launch of CARDAMYST™ (etripamil) nasal spray following the December 13, 2025 FDA PDUFA date. The company strengthened commercial capabilities and anticipates a quick market entry upon approval. Recent clinical data demonstrated etripamil's consi...
11-12 12:01
